MarketFriction

Krebs Biochemicals & Industries Ltd

NSE KREBSBIO · BSE 524518 · Pharmaceuticals
₹68.05 +13.04%
NSE close2026-10-01
52 week range38.33 - 76.85
Market cap₹130 Cr.
Price band 20% Delivery 45.9%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales14.8912.9811.9712.8912.8611.476.105.484.177.276.816.98
Expenses15.7915.0715.0915.0815.5816.1811.517.576.976.977.676.16
Operating Profit-0.90-2.09-3.12-2.19-2.72-4.71-5.41-2.09-2.800.30-0.860.82
OPM %-6.04%-16.10%-26.07%-16.99%-21.15%-41.06%-88.69%-38.14%-67.15%4.13%-12.63%11.75%
Other Income0.170.030.210.030.090.250.340.010.010.002.000.16
Interest1.131.191.271.321.421.561.611.651.731.791.911.88
Depreciation1.711.731.671.691.711.721.571.601.621.631.571.59
Profit before tax-3.57-4.98-5.85-5.17-5.76-7.74-8.25-5.33-6.14-3.12-2.34-2.49
Tax %0.00%0.00%0.00%0.00%0.00%0.00%0.24%0.00%0.00%0.00%0.00%0.00%
Net Profit-3.57-4.98-5.85-5.17-5.76-7.74-8.27-5.32-6.14-3.13-2.34-2.48
EPS in Rs-1.66-2.31-2.71-2.40-2.67-3.59-3.84-2.47-2.85-1.45-1.09-1.15
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1334483354605250432425
Expenses141141585271946859582928
Operating Profit-12-8-8-10-19-18-34-16-9-15-5-3
OPM %-1,088%-248%-22%-20%-56%-33%-57%-30%-17%-35%-23%-10%
Other Income1-0-1001110122
Interest135666535677
Depreciation444455677766
Profit before tax-16-16-18-20-29-28-45-25-20-27-17-14
Tax %0%0%0%0%0%0%0%0%0%0%0%
Net Profit-16-16-18-20-29-28-45-25-20-27-17-14
EPS in Rs-10.33-9.67-10.73-12.03-16.04-14.45-20.65-11.45-9.15-12.50-7.85-6.54
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth35%-15%-23%-30%
Compounded Profit Growth0%7%10%48%
Stock Price CAGR-4%-20%-6%-21%
Return on Equity%%%%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital101314141718202222222222
Reserves9-0-12-32-31-43-62-97-121-141-168-184
Borrowings613148565366111143183194212225
Other Liabilities29737387103939112291104103101
Total Liabilities108116122126142134159190175178169163
Fixed Assets5893102101101105118139147150146142
CWIP01144341284232
Investments000000000000
Other Assets501316213824294324262020
Total Assets108116122126142134159190175178169163
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-45-15-11-64-36-15-17-252-8-2
Cash from Investing Activity-3-4-5-3-4-10-23-23-13-8-5-4
Cash from Financing Activity541316917293840376136
Net Cash Flow6-6-0017-171-1-000-0
Free Cash Flow-48-23-17-9-1-45-40-41-36-5-11-5
CFO/OP924%123%140%83%-40%191%83%51%157%-27%52%35%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1018032222541400
Inventory Days14,7042,162337142345234230170543396
Days Payable32,2504,3605103395212923402171,0511,192
Cash Conversion Cycle-17,536-2,018-170-175-174-57-106-44-494-7950
Working Capital Days-6,532-2,132-275-315-267-187-261-232-322-787-1,593
ROCE %-26%-26%-26%-36%-57%-40%-57%-29%-19%-30%-15%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%
FIIs0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%
Public26.76%26.77%26.75%26.75%26.76%26.76%26.75%26.76%26.76%26.76%26.77%26.76%
No. of Shareholders9,0308,9908,9098,8489,4259,0918,7989,1188,9128,7108,5538,521

Fundamentals

Market Cap₹ 130 Cr.
Current Price₹ 59.0
Book Value₹ -75.5
ROCE-15.4 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-30%
Compounded Profit Growth (TTM)48%
Standalone figures.
Valuation
Market capRs 147 Cr
Enterprise valueRs 371 Cr
Price to book-0.90x
Price to sales5.82x
EV / sales14.72x
Earnings yield-9.60%
P/B, 3-year average-0.87x
P/B, 5-year average-1.59x
Profitability
Operating margin (excl. other income)-22.97%
Operating margin (incl. other income)-14.41%
EBITDA margin-1.47%
Pre-tax margin-55.85%
Net profit margin-55.85%
Net margin, latest quarter-35.53%
ROE10.96%
ROCE-15.37%
ROA-10.19%
ROE, 3-year average16.43%
ROCE, 3-year average-21.43%
ROA, 3-year average-12.29%
ROE, 5-year average30.64%
ROCE, 5-year average-30.05%
ROA, 5-year average-15.19%
ROIC (approx.)-10.94%
Other income / net worth-1.25%
Growth
Sales growth (latest year)-45.21%
Sales CAGR, 3 years-23.07%
Sales CAGR, 5 years-15.07%
Sales growth QoQ2.50%
Sales growth YoY (latest quarter)27.37%
Per share
EPS (TTM)Rs -6.54
EPS (latest year)Rs -7.85
EPS (latest quarter)Rs -1.15
EPS, 3-year averageRs -9.83
EPS, 5-year averageRs -12.32
Book value per shareRs -75.49
Sales per shareRs 11.70
Cash flow per shareRs -0.89
Free cash flow per shareRs -2.32
Efficiency
Asset turnover0.15x
Fixed asset turnover0.17x
Inventory turnover2.26x
Inventory days161 days
Creditor days1192 days
Cash conversion cycle0 days
Working capital days-1593 days
Leverage
Total debtRs 225 Cr
Cash and bankRs 0 Cr
Net debtRs 225 Cr
Debt to equity-1.38x
Interest coverage-0.93x
Owners' fund to total sources-99.70%
Debt to assets137.73%
Cash flow
Cash from Operating Activity (latest year)Rs -2 Cr
Cash from Investing Activity (latest year)Rs -4 Cr
Cash from Financing Activity (latest year)Rs 6 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -5 Cr
FCFE (approx.: FCF + change in debt)Rs 8 Cr
Statement figures
Net sales (TTM)Rs 25 Cr
Net sales (latest year)Rs 24 Cr
Sales (latest quarter)Rs 7 Cr
Operating profit excl. other income (latest year)Rs -5 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -8 Cr
Profit before tax (TTM)Rs -14 Cr
Net profit (TTM)Rs -14 Cr
Net profit (latest year)Rs -17 Cr
Net profit (latest quarter)Rs -2 Cr
Depreciation (TTM)Rs 6 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 13 Cr
Total expenditure (latest year)Rs 29 Cr
Total income (latest year)Rs 26 Cr
Share capitalRs 22 Cr
ReservesRs -184 Cr
Shareholders' fundsRs -163 Cr
Total assetsRs 163 Cr
Net blockRs 142 Cr
Capital work in progressRs 2 Cr
InventoryRs 6 Cr
Other liabilitiesRs 101 Cr
Shares outstanding (crore)2.16
Ownership
Promoter holding72.74% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
PeriodKREBSBIONifty 50Difference
1 week+18.0%-2.8% +20.8 pts
1 month+24.9%-6.8% +31.7 pts
3 months+16.2%-7.6% +23.8 pts
6 months+71.2%+0.4% +70.8 pts
1 year-7.4%-9.9% +2.6 pts
2 years-21.8%-13.6% -8.2 pts
3 years+0.1%+14.2% -14.1 pts
5 years-61.2%+27.9% -89.1 pts

Red flags

F-score 4 of 8
seriousNegative equity Shareholders' equity is negative
lookInventory outrunning sales Inventory grew -5% vs sales -45% in 2026
lookRepeated losses Net loss in each of the last two years
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹7 Cr +27.4% vs Jun 2025. Net loss ₹2 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
DateClientSideQtyPrice
2026-10-01Vaibhav UpadhyaySELL120,26866.69
2026-10-01Vaibhav UpadhyayBUY74266.78
Ex-dateActionFactor
2023-09-20Annual General Meeting
2021-09-15 Annual General Meeting
2020-09-16 Annual General Meeting
2019-09-13 Annual General Meeting
2019-01-31 Rights 21:100 @ Premium Rs 76 Per Share
2018-08-30 Annual General Meeting
2017-09-14 Annual General Meeting
2016-09-20 Annual General Meeting
2015-09-23 Annual General Meeting
2013-12-16Annual General Meeting
2012-09-20Annual General Meeting
2011-09-22Annual General Meeting
2010-08-16Annual General Meeting
2009-09-03Annual General Meeting
2008-09-15Annual General Meeting
2007-09-19Agm Bc End Date Revised
DateTypeWhat it says
2026-09-29Shareholder meetingVoting results.
2026-09-29Shareholder meetingProceedings of Annual General Meeting held on September 29, 2026
2026-09-07UpdatesMachine Readable financial results for the quarter ended 30.06.2026..
2026-09-04Shareholder meetingNotice of Annual General Meeting to be held on September 29, 2026
2026-08-06Board meeting outcomeKrebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-06-26Scheme of ArrangementScheme of Arrangement
2026-06-26Board meeting outcomeOutcome of Board MEETING
2026-05-21Board meeting outcomeKrebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-10Price movementSignificant movement in price has been observed in Krebs Biochemicals and Industries Limited. The Exchange, in order to ensure that investors have lat...
2026-04-09Disclosure under SEBI TakeovIpca Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Sub...
2026-04-09Disclosure under SEBI TakeovAvinash Ravi For and on behalf of Dr. R.T. Ravi Mrs. Hemalata Ravi Mr. Avinash Ravi Mr. Aditya Ravi Mr. Ajay Ravi has Submitted to the Exchange a copy...
2026-04-08Price movementSignificant movement in price has been observed in Krebs Biochemicals and Industries Limited. The Exchange, in order to ensure that investors have lat...
2026-02-09Board meeting outcomeKrebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2026-01-05Updates.
2025-12-03UpdatesRTA Report on Re-lodgement of transfer requests of physical shares.
2025-11-18UpdatesReport on Re-lodgement of transfer requests of physical shares.
2025-11-04Board meeting outcomeKrebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
2025-11-04Board meeting outcomeBoard meeting held on November 04, 2025.
2025-10-08UpdatesRe-lodgement of transfer requests of physical shares.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)Less than 100 unique PAN traded in previous 30 daysLoss making
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03